Olmutinib (Figure 48) is a third-generation EGFR-TKI that was approved in May 2016, in South Korea for use in the treatment of patients with NSCLC with a T790M-positive mutation [123]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.